Prognostic factors in idiopathic membranous nephropathy

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
L J ReichertJ F Wetzels

Abstract

Membranous nephropathy is the most frequent cause of glomerulonephritis in adults with nephrotic syndrome. Approximately one quarter of the patients develop end-stage renal disease. Another quarter enters complete remission during follow-up. Treating all patients with membranous nephropathy with immunosuppressive drugs would unnecessarily expose at least one quarter of the patients to these toxic drugs. Identifying patients at highest risk would allow tailor-made treatment. Many risk factors have been found, such as male sex, HLA type DR3+/B8+, white race, advanced age, and tubulointerstitial changes or focal sclerosis found with renal biopsy. In addition, nephrotic syndrome, elevation of immunoglobulin G excretion or beta2-microglobulin excretion, low serum albumin, high serum cholesterol, an elevation of urinary excretion of complement activation products, impaired renal function at diagnosis, and, finally, hypertension are associated with a higher risk of renal function deterioration during follow-up. We have critically reviewed the literature and summarized the clinical significance of the above-mentioned risk factors in predicting subsequent renal function deterioration in patients with membranous nephropathy.

Citations

Nov 13, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Shina Menon, Rudolph P Valentini
May 19, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Jan A J G van den BrandJack F M Wetzels
Dec 14, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Jan A J G van den BrandJack F M Wetzels
Jun 1, 2006·Rheumatology International·Eduardo F BorbaEloisa Bonfá
Oct 11, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Rudolph P ValentiniAbubakr Imam
Dec 10, 2013·Néphrologie & thérapeutique·Lucile Mercadal
Nov 27, 2007·Expert Opinion on Pharmacotherapy·Piero RuggenentiGiuseppe Remuzzi
Sep 22, 2012·Pathology, Research and Practice·Ivica HorvaticKresimir Galesic
Aug 5, 1999·Kidney International·B E Marx, M Marx
Apr 17, 2004·Kidney International·Hideo ShiikiUNKNOWN Research Group on Progressive Renal Diseases in Japan
Mar 28, 2012·Advances in Chronic Kidney Disease·Paul E Segal, Michael J Choi
Aug 3, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G MillerG Appel
Jul 31, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Amanda J BrantenJack F Wetzels
Dec 25, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Alexandre DumoulinAlain Meyrier
Nov 29, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Peggy W G du Buf-VereijkenJack F M Wetzels
Sep 11, 2012·International Journal of Immunogenetics·C BurtP Dyer
Jun 26, 2014·PloS One·Makoto YamaguchiShoichi Maruyama
Mar 1, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Julia M HofstraJack F M Wetzels
Jul 9, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Julia M Hofstra, Jack F M Wetzels
May 26, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Masahiro EriguchiAtsumi Harada
Oct 6, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·George ChinJennet M Harvey
Aug 30, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Claude J RenaudLuc Turmel-Rodrigues
Mar 3, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Peggy W G du Buf-VereijkenUNKNOWN Membranous Nephropathy Study Group
Mar 28, 2008·Nature Clinical Practice. Nephrology·Martin H de BorstGiuseppe Remuzzi
May 15, 2007·Journal of the American Society of Nephrology : JASN·Vivekanand JhaVinay Sakhuja
Nov 26, 2004·Journal of the American Society of Nephrology : JASN·Amanda J W BrantenJack F Wetzels
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Piero RuggenentiGiuseppe Remuzzi
Jul 24, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Daniel C Cattran, Joseph Kim
Jul 4, 2013·Nature Reviews. Nephrology·Julia M HofstraJack F M Wetzels

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Julia M HofstraJ F Wetzels
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Peggy W du Buf-VereijkenJ F Wetzels
International Urology and Nephrology
Ljubica DjukanovićVladisav Stefanović
© 2021 Meta ULC. All rights reserved